Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disease caused by <i>Aspergillus fumigatus</i> (<i>Af</i>), prevalent in persons with cystic fibrosis (CF) or asthma. In ABPA, <i>Af</i> proteases drive a T-helper cell-2 (Th2)-mediated allergic...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Journal of Fungi |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2309-608X/10/9/656 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850260757976973312 |
|---|---|
| author | Paulami Chatterjee Carson Tyler Moss Sarah Omar Ekroop Dhillon Carlos Daniel Hernandez Borges Alan C. Tang David A. Stevens Joe L. Hsu |
| author_facet | Paulami Chatterjee Carson Tyler Moss Sarah Omar Ekroop Dhillon Carlos Daniel Hernandez Borges Alan C. Tang David A. Stevens Joe L. Hsu |
| author_sort | Paulami Chatterjee |
| collection | DOAJ |
| description | Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disease caused by <i>Aspergillus fumigatus</i> (<i>Af</i>), prevalent in persons with cystic fibrosis (CF) or asthma. In ABPA, <i>Af</i> proteases drive a T-helper cell-2 (Th2)-mediated allergic immune response leading to inflammation that contributes to permanent lung damage. Corticosteroids and antifungals are the mainstays of therapies for ABPA. However, their long-term use has negative sequelae. The treatment of patients with CF (pwCF) has been revolutionized by the efficacy of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Pharmacological improvement in CFTR function with highly effective elexacaftor/tezacaftor/ivacaftor (ETI) provides unprecedented improvements in lung function and other clinical outcomes of pwCF. The mechanism behind the improvement in patient outcomes is a continued topic of investigation as our understanding of the role of CFTR function evolves. As ETI therapy gains traction in CF management, understanding its potential impact on ABPA, especially on the allergic immune response pathways and <i>Af</i> infection becomes increasingly crucial for optimizing patient outcomes. This literature review aims to examine the extent of these findings and expand our understanding of the already published research focusing on the intersection between ABPA therapeutic approaches in CF and the rapid impact of the evolving CFTR modulator landscape. While our literature search yielded limited reports specifically focusing on the role of CFTR modulator therapy on CF-ABPA, findings from epidemiologic and retrospective studies suggest the potential for CFTR modulator therapies to positively influence pulmonary outcomes by addressing the underlying pathophysiology of CF-ABPA, especially by decreasing inflammatory response and <i>Af</i> colonization. Thus, this review highlights the promising scope of CFTR modulator therapy in decreasing the overall prevalence and incidence of CF-ABPA. |
| format | Article |
| id | doaj-art-104ba0b62eec4f2d9da2af2b783efc84 |
| institution | OA Journals |
| issn | 2309-608X |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Fungi |
| spelling | doaj-art-104ba0b62eec4f2d9da2af2b783efc842025-08-20T01:55:34ZengMDPI AGJournal of Fungi2309-608X2024-09-0110965610.3390/jof10090656Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ModulatorsPaulami Chatterjee0Carson Tyler Moss1Sarah Omar2Ekroop Dhillon3Carlos Daniel Hernandez Borges4Alan C. Tang5David A. Stevens6Joe L. Hsu7Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA 94305, USADepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94304, USADivision of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA 94305, USADivision of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA 94305, USADepartment of Internal Medicine, Alta Bates Summit Medical Center, Sutter Health, Oakland, CA 94609, USADepartment of Medicine, Keck School of Medicine, Los Angeles, CA 90089, USADivision of Infectious Diseases and Geographic Medicine, Stanford University Medical School, Stanford, CA 94305, USADivision of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA 94305, USAAllergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disease caused by <i>Aspergillus fumigatus</i> (<i>Af</i>), prevalent in persons with cystic fibrosis (CF) or asthma. In ABPA, <i>Af</i> proteases drive a T-helper cell-2 (Th2)-mediated allergic immune response leading to inflammation that contributes to permanent lung damage. Corticosteroids and antifungals are the mainstays of therapies for ABPA. However, their long-term use has negative sequelae. The treatment of patients with CF (pwCF) has been revolutionized by the efficacy of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Pharmacological improvement in CFTR function with highly effective elexacaftor/tezacaftor/ivacaftor (ETI) provides unprecedented improvements in lung function and other clinical outcomes of pwCF. The mechanism behind the improvement in patient outcomes is a continued topic of investigation as our understanding of the role of CFTR function evolves. As ETI therapy gains traction in CF management, understanding its potential impact on ABPA, especially on the allergic immune response pathways and <i>Af</i> infection becomes increasingly crucial for optimizing patient outcomes. This literature review aims to examine the extent of these findings and expand our understanding of the already published research focusing on the intersection between ABPA therapeutic approaches in CF and the rapid impact of the evolving CFTR modulator landscape. While our literature search yielded limited reports specifically focusing on the role of CFTR modulator therapy on CF-ABPA, findings from epidemiologic and retrospective studies suggest the potential for CFTR modulator therapies to positively influence pulmonary outcomes by addressing the underlying pathophysiology of CF-ABPA, especially by decreasing inflammatory response and <i>Af</i> colonization. Thus, this review highlights the promising scope of CFTR modulator therapy in decreasing the overall prevalence and incidence of CF-ABPA.https://www.mdpi.com/2309-608X/10/9/656allergic bronchopulmonary aspergillosiscystic fibrosis<i>Aspergillus fumigatus</i><i>Aspergillus</i> proteasesallergic inflammationasthma |
| spellingShingle | Paulami Chatterjee Carson Tyler Moss Sarah Omar Ekroop Dhillon Carlos Daniel Hernandez Borges Alan C. Tang David A. Stevens Joe L. Hsu Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Journal of Fungi allergic bronchopulmonary aspergillosis cystic fibrosis <i>Aspergillus fumigatus</i> <i>Aspergillus</i> proteases allergic inflammation asthma |
| title | Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators |
| title_full | Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators |
| title_fullStr | Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators |
| title_full_unstemmed | Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators |
| title_short | Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators |
| title_sort | allergic bronchopulmonary aspergillosis abpa in the era of cystic fibrosis transmembrane conductance regulator cftr modulators |
| topic | allergic bronchopulmonary aspergillosis cystic fibrosis <i>Aspergillus fumigatus</i> <i>Aspergillus</i> proteases allergic inflammation asthma |
| url | https://www.mdpi.com/2309-608X/10/9/656 |
| work_keys_str_mv | AT paulamichatterjee allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators AT carsontylermoss allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators AT sarahomar allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators AT ekroopdhillon allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators AT carlosdanielhernandezborges allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators AT alanctang allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators AT davidastevens allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators AT joelhsu allergicbronchopulmonaryaspergillosisabpaintheeraofcysticfibrosistransmembraneconductanceregulatorcftrmodulators |